PARP1 and neoplasm: By pharmacologically targeting the synthetic lethal partner, PARP, the cytotoxic effect mainly occurs in tumor cells with hampered BRCA function, hence selectively eliminating tumor cells and exhibiting limited cytotoxic effect in non-cancerous tissue due to its still functional BRCA [10].